Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA 1c in New-Onset Type 1 Diabetes

A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that ) low-dose ATG/GCSF or ) low-dose ATG...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2018-09, Vol.41 (9), p.1917
Hauptverfasser:	Haller, Michael J, Schatz, Desmond A, Skyler, Jay S, Krischer, Jeffrey P, Bundy, Brian N, Miller, Jessica L, Atkinson, Mark A, Becker, Dorothy J, Baidal, David, DiMeglio, Linda A, Gitelman, Stephen E, Goland, Robin, Gottlieb, Peter A, Herold, Kevan C, Marks, Jennifer B, Moran, Antoinette, Rodriguez, Henry, Russell, William, Wilson, Darrell M, Greenbaum, Carla J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antilymphocyte Serum - administration & dosage Antilymphocyte Serum - adverse effects C-Peptide - blood Child Cytoprotection - drug effects Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - physiopathology Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Female Glycated Hemoglobin - drug effects Granulocyte Colony-Stimulating Factor - administration & dosage Granulocyte Colony-Stimulating Factor - adverse effects Humans Insulin-Secreting Cells - drug effects Insulin-Secreting Cells - physiology Male Pilot Projects Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that ) low-dose ATG/GCSF or ) low-dose ATG alone would slow the decline of β-cell function in patients with new-onset T1D (duration
ISSN:	1935-5548
DOI:	10.2337/dc18-0494